205 related articles for article (PubMed ID: 9061424)
1. The efficacy of urinary cytology in the detection of recurrent bladder tumours.
Baltaci S; Süzer O; Ozer G; Bedük Y; Göğüş O
Int Urol Nephrol; 1996; 28(5):649-53. PubMed ID: 9061424
[TBL] [Abstract][Full Text] [Related]
2. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
3. Human complement factor H related protein test for monitoring bladder cancer.
Raitanen MP; Marttila T; Nurmi M; Ala-Opas M; Nieminen P; Aine R; Tammela TL;
J Urol; 2001 Feb; 165(2):374-7. PubMed ID: 11176376
[TBL] [Abstract][Full Text] [Related]
4. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
5. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
6. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
8. Are cystoscopy and urinary cytology sufficient to identify candidates for subsequent biopsy after bacillus Calmette-Guérin treatment in patients with bladder carcinoma in situ?
Haase RN; Harving N
Scand J Urol; 2015; 49(4):338-40. PubMed ID: 25660358
[No Abstract] [Full Text] [Related]
9. The predictive value of flow cytometry and urinary cytology in the followup of patients with transitional cell carcinoma of the bladder.
Giella JG; Ring K; Olsson CA; Karp FS; Benson MC
J Urol; 1992 Aug; 148(2 Pt 1):293-6. PubMed ID: 1635121
[TBL] [Abstract][Full Text] [Related]
10. Urine cytology in the follow-up of patients with transitional cell carcinoma of the urinary bladder: is that enough as a single method?
Raica M; Miclea F; Ioiart I; Minciu R; Drăgan P
Rom J Morphol Embryol; 1998; 44(1-4):173-8. PubMed ID: 15678859
[TBL] [Abstract][Full Text] [Related]
11. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
[TBL] [Abstract][Full Text] [Related]
12. [Urine cytology and urine markers. Significance for clinical practice].
Tritschler S; Zaak D; Knuechel R; Stief CG
Urologe A; 2006 Nov; 45(11):W1441-7; quiz W1448. PubMed ID: 17063350
[TBL] [Abstract][Full Text] [Related]
13. The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies.
Raitanen MP;
World J Urol; 2008 Feb; 26(1):45-50. PubMed ID: 18180926
[TBL] [Abstract][Full Text] [Related]
14. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic efficacy of the combination of urine cytology, urine analysis and history in the follow-up of bladder carcinoma.
Meuleman EJ; Delaere KP
Br J Urol; 1988 Aug; 62(2):150-3. PubMed ID: 3408887
[TBL] [Abstract][Full Text] [Related]
16. Analysis of false-positive BTA STAT test results in patients followed up for bladder cancer.
Raitanen MP; Kaasinen E; Lukkarinen O; Kauppinen R; Viitanen J; Liukkonen T; Tammela TL;
Urology; 2001 Apr; 57(4):680-4. PubMed ID: 11306380
[TBL] [Abstract][Full Text] [Related]
17. Combinations of urine-based tumour markers in bladder cancer surveillance.
Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
[TBL] [Abstract][Full Text] [Related]
18. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the BTAstat test, NMP22, and voided urine cytology in the detection of primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Mitropoulos D; Botsoli-Stergiou E; Constantinides C; Giannopoulou M; Choremi-Papadopoulou H
Urology; 2000 Jun; 55(6):871-5. PubMed ID: 10840098
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guérin bacillus for superficial bladder cancer.
Mack D; Frick J
Urol Int; 1994; 52(4):204-7. PubMed ID: 8030167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]